Summary
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
History
Mustang Bio, Inc. was founded in 2015 and is headquartered in Fort Lee, New Jersey with offices in Gaithersburg, Maryland, South San Francisco and Cambridge, Massachusetts. Mustang has established strategic collaborations with Benaroya Research Institute and Kite, A Gilead Company.
Mission
Mustang Bio is committed to unlocking the potential of the human genome, through both cellular therapy and gene therapy to make a difference in patients lives and to revolutionize healthcare for these patients.
Vision
Mustang Bio vision is to become the premier gene and cell therapy company, developing and commercializing innovative treatments for cancer, genetic and rare childhood diseases and autoimmune conditions.
Key Team
Dr. Knut Niss (Chief Technology Officer)
Mr. Matthew Wein J.D. (VP & Gen. Counsel)
Ms. Debra Manning SPHR (Sr. VP of HR)
Dr. Bruce Dezube M.D. (Sr. VP & Head of Clinical Devel.)
Mr. Greg Furrow M.S. (Sr. VP of Quality)
Ms. Robyn M. Hunter (Corp. Sec.)
Recognition and Awards
Mustang Bio has been honored multiple times for its achievements in the field, including recognition from the Patent Trial and Appeal Board, Bio Generation and TiE 50 awards.
References
